ProCE Banner Activity

Selective CDK4/6 Inhibitors: A New Paradigm With Expanding Application in Cancer Care

Multimedia
In this Webcast from a satellite symposium at the 2017 annual meeting in Chicago, expert insights on the biology and emerging role of CDK4/6 inhibitors in multiple tumor types are provided by Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD.

Released: July 13, 2017

Expiration: July 12, 2018

No longer available for credit.

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Gary K. Schwartz

Gary K. Schwartz, MD

Professor of Medicine
Department of Medicine
Columbia University
Chief, Division of Hematology and Oncology
Department of Medicine
Columbia University Medical Center
New York, New York

Geoffrey Shapiro

Geoffrey Shapiro, MD, PhD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Early Drug Development Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Learning Objectives

  • Discuss the preclinical data and scientific rationale for targeting CDK4/6 in cancer care
  • Describe how selective CDK inhibition has improved efficacy and reduced toxicity when compared with first-generation, nonselective CDK inhibitors
  • Describe the similarities and differences among the CDK4/6 inhibitors
  • Identify potential biomarkers of sensitivity to CDK4/6 inhibitors
  • Evaluate the available clinical data on abemaciclib, palbociclib, and ribociclib in multiple tumor types beyond ER-positive breast cancer
  • Summarize mechanisms of acquired resistance to CDK4/6 inhibitors
  • Explore current therapeutic strategies and ongoing clinical trials of CDK4/6 inhibitors alone or in combination with other agents

Program Director Disclosure

Program Director

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Novartis, and Pfizer.

Faculty Disclosure

Primary Author

Gary K. Schwartz, MD

Professor of Medicine
Department of Medicine
Columbia University
Chief, Division of Hematology and Oncology
Department of Medicine
Columbia University Medical Center
New York, New York

Gary K. Schwartz, MD, has no real or apparent conflicts of interest to report.

Geoffrey Shapiro, MD, PhD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Early Drug Development Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Geoffrey Shapiro, MD, PhD, has disclosed that he has received consulting fees from G1 Therapeutics, Lilly, Pfizer, Roche, and Vertex and funds for research support from Lilly and Pfizer.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.